Drug Monograph

Drug/Drug Class:	**Lucentis® (ranibizumab) solution for injection/ Macular Degeneration Agents**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Lucentis® is now available in a 0.3 mg carton that contains a single-use, prefilled syringe designed to deliver 0.05 ml of 6 mg/ml ranibizumab solution.
Manufacturer:	Genentech, Inc., South San Francisco, CA 94080
Indications:	Lucentis® is indicated for the treatment of patients with Neovascular (Wet) age –related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Costs:	$1,165.32 per syringe of Lucentis® 0.3 mg/0.05 ml. Maximum Allowable Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ No PA Required

Prepared By: Luke Boehmer PharmD
Date: August 17, 2018